A Double-Blind, Crossover, Randomized, Placebo-Controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-Phase Insulin Secretion in Type 2 Diabetic Patients
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Taspoglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Roche
- 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 20 Jan 2010 New source identified and integrated Roche (BP21844).
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.